Key Insights:
- Injective ETF receives Nasdaq listing approval under INJC; trading awaits an effective S-1.
- Canary Capital plans to stake at least 90% of INJ holdings, with BitGo providing custody.
- The INJ price was reported near $7.64, with $7.30 support and 8.00–8.20 targets in focus.
Canary Capital has secured Nasdaq listing approval for its Staked Injective ETF, according to a November 3 SEC filing. The fund plans to trade under INJC, although public sales must wait until its S-1 registration becomes effective. Under normal circumstances, its strategy includes staking at least 90% of its INJ holdings, with BitGo providing custody.
The development comes as INJ attempts to recover above $7.30. Buyers also face resistance near $7.92. Traders are watching whether the token can hold that breakout and approach resistance near 8.00–$8.20.
Injective ETF Filing Confirms Nasdaq Listing Approval
The November 3 Form 8-A12B registers the fund’s common shares for listing on Nasdaq. According to Eagle.inj on X, the exchange has approved the listing application and references a prospectus filed on November 2.
The Injective ETF would give brokerage customers a way to hold exposure through shares rather than managing tokens themselves. That could simplify access for investors who already use traditional securities accounts.
However, the filing does not provide a date for the first trading session. Nasdaq listing approval establishes the exchange arrangement, while an effective S-1 remains a separate requirement for public sales.
The Injective ETF filing also provides no evidence of subscriptions or institutional inflows. Those figures would require separate disclosures once investors can participate. A listing decision alone cannot establish how much new demand the product will generate.
The prospectus also says Injective Foundation indicated plans to purchase up to $15 million in seed shares. That stated intention does not establish completed fundraising or evidence of broader institutional participation.
Injective ETF Staking Plan Puts BitGo in Custody Role
Canary Capital expects to stake at least 90% of the fund’s INJ under normal conditions. It can reserve tokens for redemptions, expenses, and other operational needs.
BitGo will safeguard the assets, while selected staking providers operate validator nodes. The Injective ETF seeks to earn additional INJ through network staking, alongside exposure to token prices.
The prospectus sets an annual sponsor fee of 1.10% of the fund’s INJ holdings. It also explains that expenses can reduce the tokens represented by each share when staking rewards fall short.
Staking therefore adds a source of potential returns, alongside costs and network risks. The Injective ETF prospectus describes a 21-day unbonding period for withdrawing delegated tokens.
During that period, those tokens earn no staking rewards and cannot be transferred. Staking rewards vary with network conditions, so the allocation does not represent a promised annual yield.
INJ Price Clears $7.30 as Traders Assess Higher Targets
Technical analyst Trader Symba has identified a wedge breakout followed by a retest. The analyst highlighted $7.30 as the level buyers needed to reclaim.
The reported INJ price of $7.64 already exceeded the analyst’s first target of $7.55. That leaves the 8.00–8.20 range as the next projected resistance area in that assessment. From $7.64, those targets imply gains of roughly 4.7% and 7.3%, respectively. Both projections depend on the reported setup holding.
The 20-day moving average is near $7.92, and the Relative Strength Index is around 50. Those readings suggest the recovery still faced overhead resistance, despite its advance above the shorter seven-day average.
Although the Injective ETF headlines coincided with the recovery, the available figures do not isolate their influence. Broader market activity could also affect the INJ price.
Holding $7.30 would preserve the reported breakout structure. A retreat below that level would weaken the setup, while resistance near $7.92 sits before the higher targets.
